Clinically, nearly irrespective of their underlying genetic defects, all cases of CLL are exquisitely sensitive to BCL2 inhibition, usually with a low nanomolar EC50 in vitro. Here, BCL2 is linked to B-cell chronic lymphocytic leukemia.